Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2

Nicole C. Panarelli, Rhonda K. Yantiss, Matthew M. Yeh, Yifang Liu, Yao Tseng Chen

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Cadherin 17 (CDH17) is a cell adhesion molecule expressed in intestinal epithelium and transcriptionally regulated by CDX2. We compared the usefulness of CDH17 as an immunohistochemical intestinal marker to that of CDX2 in gastrointestinal and extragastrointestinal carcinomas and nonneoplastic tissues. Nonneoplastic intestinal and pancreatic duct epithelia were CDH17-positive. Most esophageal (79%), gastric (86%), and colonic (99%) adenocarcinomas were CDH17-positive/CDX2-positive, whereas 1% of colonic, 18% of esophageal, and 10% of gastric adenocarcinomas were CDH17-negative/CDX2-negative. Rare colonic, esophageal, and gastric adenocarcinomas were CDH17-positive/CDX2-negative (1%, 3%, and 4%, respectively), and none were CDH17-negative/CDX2-positive. Diffuse CDH17 was also observed in all metastatic colon carcinomas, 20% of which were only focally CDX2-positive. Of intestinal low-grade neuroendocrine tumors, 74% coexpressed CDX2 and CDH17. CDH17 was also positive in 12% of pancreatic and 24% of bronchial neuroendocrine tumors, all of which were CDX2-negative. Pancreatic adenocarcinomas and cholangiocarcinomas were more frequently CDH17-positive than CDX2-positive (50% vs 27%, 53% vs 27%). One (2%) hepatocellular carcinoma was CDH17-positive/CDX2-negative. Nine percent of non-small cell lung cancers and 7% of endometrial carcinomas were CDH17-positive, whereas 3% of lung, 5% of endometrial, 3% of ovarian, and 2% of breast carcinomas were CDX2-positive. Thus, CDH17 is slightly more sensitive than CDX2 when detecting gastrointestinal adenocarcinomas. Copyright

Original languageEnglish (US)
Pages (from-to)211-222
Number of pages12
JournalAmerican Journal of Clinical Pathology
Volume138
Issue number2
DOIs
StatePublished - Aug 2012
Externally publishedYes

Fingerprint

Cadherins
Adenocarcinoma
Stomach
Neuroendocrine Tumors
Carcinoma
Cholangiocarcinoma
Pancreatic Ducts
Cell Adhesion Molecules
Intestinal Mucosa
Endometrial Neoplasms
Non-Small Cell Lung Carcinoma
Hepatocellular Carcinoma
Colon
Epithelium

Keywords

  • Cholangiocarcinoma
  • Colonic
  • Immunohistochemistry
  • Intestinal differentiation
  • Metastatic
  • Neuroendocrine
  • Pancreatobiliary

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2. / Panarelli, Nicole C.; Yantiss, Rhonda K.; Yeh, Matthew M.; Liu, Yifang; Chen, Yao Tseng.

In: American Journal of Clinical Pathology, Vol. 138, No. 2, 08.2012, p. 211-222.

Research output: Contribution to journalArticle

Panarelli, Nicole C. ; Yantiss, Rhonda K. ; Yeh, Matthew M. ; Liu, Yifang ; Chen, Yao Tseng. / Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2. In: American Journal of Clinical Pathology. 2012 ; Vol. 138, No. 2. pp. 211-222.
@article{ef6ab6ffc2e04e868cc5fec73f688d0f,
title = "Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2",
abstract = "Cadherin 17 (CDH17) is a cell adhesion molecule expressed in intestinal epithelium and transcriptionally regulated by CDX2. We compared the usefulness of CDH17 as an immunohistochemical intestinal marker to that of CDX2 in gastrointestinal and extragastrointestinal carcinomas and nonneoplastic tissues. Nonneoplastic intestinal and pancreatic duct epithelia were CDH17-positive. Most esophageal (79{\%}), gastric (86{\%}), and colonic (99{\%}) adenocarcinomas were CDH17-positive/CDX2-positive, whereas 1{\%} of colonic, 18{\%} of esophageal, and 10{\%} of gastric adenocarcinomas were CDH17-negative/CDX2-negative. Rare colonic, esophageal, and gastric adenocarcinomas were CDH17-positive/CDX2-negative (1{\%}, 3{\%}, and 4{\%}, respectively), and none were CDH17-negative/CDX2-positive. Diffuse CDH17 was also observed in all metastatic colon carcinomas, 20{\%} of which were only focally CDX2-positive. Of intestinal low-grade neuroendocrine tumors, 74{\%} coexpressed CDX2 and CDH17. CDH17 was also positive in 12{\%} of pancreatic and 24{\%} of bronchial neuroendocrine tumors, all of which were CDX2-negative. Pancreatic adenocarcinomas and cholangiocarcinomas were more frequently CDH17-positive than CDX2-positive (50{\%} vs 27{\%}, 53{\%} vs 27{\%}). One (2{\%}) hepatocellular carcinoma was CDH17-positive/CDX2-negative. Nine percent of non-small cell lung cancers and 7{\%} of endometrial carcinomas were CDH17-positive, whereas 3{\%} of lung, 5{\%} of endometrial, 3{\%} of ovarian, and 2{\%} of breast carcinomas were CDX2-positive. Thus, CDH17 is slightly more sensitive than CDX2 when detecting gastrointestinal adenocarcinomas. Copyright",
keywords = "Cholangiocarcinoma, Colonic, Immunohistochemistry, Intestinal differentiation, Metastatic, Neuroendocrine, Pancreatobiliary",
author = "Panarelli, {Nicole C.} and Yantiss, {Rhonda K.} and Yeh, {Matthew M.} and Yifang Liu and Chen, {Yao Tseng}",
year = "2012",
month = "8",
doi = "10.1309/AJCPKSHXI3XEHW1J",
language = "English (US)",
volume = "138",
pages = "211--222",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2

AU - Panarelli, Nicole C.

AU - Yantiss, Rhonda K.

AU - Yeh, Matthew M.

AU - Liu, Yifang

AU - Chen, Yao Tseng

PY - 2012/8

Y1 - 2012/8

N2 - Cadherin 17 (CDH17) is a cell adhesion molecule expressed in intestinal epithelium and transcriptionally regulated by CDX2. We compared the usefulness of CDH17 as an immunohistochemical intestinal marker to that of CDX2 in gastrointestinal and extragastrointestinal carcinomas and nonneoplastic tissues. Nonneoplastic intestinal and pancreatic duct epithelia were CDH17-positive. Most esophageal (79%), gastric (86%), and colonic (99%) adenocarcinomas were CDH17-positive/CDX2-positive, whereas 1% of colonic, 18% of esophageal, and 10% of gastric adenocarcinomas were CDH17-negative/CDX2-negative. Rare colonic, esophageal, and gastric adenocarcinomas were CDH17-positive/CDX2-negative (1%, 3%, and 4%, respectively), and none were CDH17-negative/CDX2-positive. Diffuse CDH17 was also observed in all metastatic colon carcinomas, 20% of which were only focally CDX2-positive. Of intestinal low-grade neuroendocrine tumors, 74% coexpressed CDX2 and CDH17. CDH17 was also positive in 12% of pancreatic and 24% of bronchial neuroendocrine tumors, all of which were CDX2-negative. Pancreatic adenocarcinomas and cholangiocarcinomas were more frequently CDH17-positive than CDX2-positive (50% vs 27%, 53% vs 27%). One (2%) hepatocellular carcinoma was CDH17-positive/CDX2-negative. Nine percent of non-small cell lung cancers and 7% of endometrial carcinomas were CDH17-positive, whereas 3% of lung, 5% of endometrial, 3% of ovarian, and 2% of breast carcinomas were CDX2-positive. Thus, CDH17 is slightly more sensitive than CDX2 when detecting gastrointestinal adenocarcinomas. Copyright

AB - Cadherin 17 (CDH17) is a cell adhesion molecule expressed in intestinal epithelium and transcriptionally regulated by CDX2. We compared the usefulness of CDH17 as an immunohistochemical intestinal marker to that of CDX2 in gastrointestinal and extragastrointestinal carcinomas and nonneoplastic tissues. Nonneoplastic intestinal and pancreatic duct epithelia were CDH17-positive. Most esophageal (79%), gastric (86%), and colonic (99%) adenocarcinomas were CDH17-positive/CDX2-positive, whereas 1% of colonic, 18% of esophageal, and 10% of gastric adenocarcinomas were CDH17-negative/CDX2-negative. Rare colonic, esophageal, and gastric adenocarcinomas were CDH17-positive/CDX2-negative (1%, 3%, and 4%, respectively), and none were CDH17-negative/CDX2-positive. Diffuse CDH17 was also observed in all metastatic colon carcinomas, 20% of which were only focally CDX2-positive. Of intestinal low-grade neuroendocrine tumors, 74% coexpressed CDX2 and CDH17. CDH17 was also positive in 12% of pancreatic and 24% of bronchial neuroendocrine tumors, all of which were CDX2-negative. Pancreatic adenocarcinomas and cholangiocarcinomas were more frequently CDH17-positive than CDX2-positive (50% vs 27%, 53% vs 27%). One (2%) hepatocellular carcinoma was CDH17-positive/CDX2-negative. Nine percent of non-small cell lung cancers and 7% of endometrial carcinomas were CDH17-positive, whereas 3% of lung, 5% of endometrial, 3% of ovarian, and 2% of breast carcinomas were CDX2-positive. Thus, CDH17 is slightly more sensitive than CDX2 when detecting gastrointestinal adenocarcinomas. Copyright

KW - Cholangiocarcinoma

KW - Colonic

KW - Immunohistochemistry

KW - Intestinal differentiation

KW - Metastatic

KW - Neuroendocrine

KW - Pancreatobiliary

UR - http://www.scopus.com/inward/record.url?scp=84865426808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865426808&partnerID=8YFLogxK

U2 - 10.1309/AJCPKSHXI3XEHW1J

DO - 10.1309/AJCPKSHXI3XEHW1J

M3 - Article

C2 - 22904132

AN - SCOPUS:84865426808

VL - 138

SP - 211

EP - 222

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 2

ER -